Pulmonology

COVID-19 hospitalizations have never fall below 6000/week, according to the ACIP; those aged 65+ have the highest inpatient rate, those aged 75+ have the highest mortality.

Your daily dose of the clinical news you may have missed.

Test your COPD IQ with these 8 questions on spirometry in COPD diagnosis, COPD exacerbations and treatment response, when to add ICS, and other topics for PCPs.

Your daily dose of the clinical news you may have missed.

New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.

A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.

AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.

AAAAI 2024. Patients with asthma who received dupilumab plus medium-dose ICS had improved lung function and asthma control vs those who received placebo plus high-dose ICS.

Conversely, increases in physical activity of just 500 METs/mins/week reduced respiratory ED visits or hospitalizations by 10-14%, according to a Korean study.

Just when the new monovalent COVID-19 vaccines were available in Sept 2023, a new variant emerged. Did the CDC get it right? What do you know about the monovalent VE?

Should you pregnant patient get the new RSV vaccine at the appropriate time during gestation or wait and have the baby receive Beyfortus after birth?

Get GOLD Report updates at-a-glance on initiating pharmacotherapy, avoiding exacerbations, treating dyspnea, how to approach using ICS, plus other topics.

Your daily dose of the clinical news you may have missed.

Approval of the application would extend the current Arexvy indication for prevention of RSV in adults aged 60 years and older; a June 2024 PDUFA date is set.

Influenza continues to rage in some parts of the US; try these 4 quick questions on vaccines you may or may not have on hand.

Updates in the Global Initiative for Obstructive Lung Disease report include using spirometry values in diagnosis and optimizing inhaled pharmacotherapy.

The combination SABA/ICS inhaler is the first of its kind and treats both acute bronchoconstriction and the inflammation that drives asthma and disease exacerbation.

The risk of cough and asthma in persons with severe depression was 3.32 times and 2.84 times higher, respectively, than that in those without depression, reported researchers.

After March 8, 2024, EUA-labeled Paxlovid will no longer be authorized for use, regardless of expiration date, according to the agency.

Past month use of cannabis was associated with 43% greater odds of asthma than no use of the drug; odds were 2-fold greater with use of blunts.

New data suggest that dupilumab is safe for long-term use among patients with moderate-to-severe asthma or OCS-dependent severe asthma.

The risk of asthma and poor outcomes was even greater among children with both conditions than among adults in this first study to compare the 2 populations.

Your daily dose of the clinical news you may have missed.

Dupilumab is the first agent approved to treat EoE in this vulnerable pediatric population.

In persons with COPD, use of the anticonvulsants was linked to a 39% increase in risk of severe disease exacerbation requiring hospital admission, study authors reported.

The National Foundation for Infectious Diseases medical director appeals to the community at large to set politics and personal grievance aside and to "first, do no harm."

Your daily dose of the clinical news you may have missed.

Use of dupilumab also eliminated the need for use of a rescue inhaler in more than one-third of treated patients and the number of inhalations needed for others.

The risk of severe CV events, including leading to death, was greatest in the first week following an exacerbation but remained significantly elevated 1 year later.

Your daily dose of the clinical news you may have missed.